Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04953143 · ClinicalTrials.gov registry record · NA
LiverPAL: A Pilot Study of Inpatient Palliative Care for Patients With Advanced Liver Disease
A NA study of Cirrhosis, Liver, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT04953143: Completed NA study of Cirrhosis, Liver, sponsored by Massachusetts General Hospital.
NCT04953143 is a NA study of Cirrhosis, Liver that has completed, run by Massachusetts General Hospital. The registered enrollment target is 25 participants, below the 241-participant average among 34 other Cirrhosis, Liver trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04953143, a NA study of Cirrhosis, Liver, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
Frequently patients with advanced liver disease experience physical and emotional symptoms during their hospitalization that can may cause a level of discomfort to both the patient and the family members that surround them. This study involves the early introduction of a team of clinicians that specialize in the lessening (palliation) of many of these discomforting symptoms. This team of clinicians is called the palliative care team and they focus on ways to improve pain and other symptom management and to assist patients and their families in coping with the physical, emotional and social issues associated with a diagnosis of advanced liver disease. The team consists of physicians and advance practice nurses who have been specially trained in the care of patients facing serious illness and their caregivers. The investigators are studying the feasibility of delivering this program, the acceptability and satisfaction with the program, and changes in the quality of life, illness understanding, and symptoms of hospitalized patients who receive the program and their caregivers. The study will use a series of questionnaires to measure the study participants' quality of life, physical symptoms, illness and prognostic understanding, and mood. Study questionnaires will be completed in the hospital, home or clinic. Qualitative interviews will be conducted with hepatology and palliative care clinicians as well as patients and caregivers.
Primary Outcome
The investigators will conduct qualitative interviews with the patients and caregivers enrolled in the open pilot phase as well as LiverPal clinicians to elicit stakeholder feedback on the intervention. The qualitative component of the exit interviews will explore 1) patients', caregivers' and clinicians' perceptions of the acceptability and content of LiverPal; 2) any barriers or challenges to providing or receiving LiverPal; and 3) suggested modifications to LiverPal to improve its delivery in
Conditions Studied
Interventions
- BEHAVIORAL LiverPal Intervention
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-01-14 |
| Est. Completion | 2022-08-16 |
| Phase | NA |
What the finished NCT04953143 record still lists
NCT04953143 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 241-participant average among 34 other Cirrhosis, Liver trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Cirrhosis, Liver appearing as the primary indexed condition, and to 1 intervention - of which LiverPal Intervention is the first listed.
NCT04953143 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04953143 about?
NCT04953143 is a clinical study titled "LiverPAL: A Pilot Study of Inpatient Palliative Care for Patients With Advanced Liver Disease". Frequently patients with advanced liver disease experience physical and emotional symptoms during their hospitalization that can may cause a level of discomfort to both the patient and the family members that surround them. This study involves the early introduction of a team of clinicians that spe...
What is the current status of trial NCT04953143?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2022-01-14. Estimated completion is 2022-08-16.
What conditions does trial NCT04953143 study?
This clinical trial studies the following conditions: Cirrhosis, Liver.
What interventions are being tested in trial NCT04953143?
The interventions under investigation include: LiverPal Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT04953143?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04953143 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis, Liver
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04953143's enrollment target sits among peer trials
25 29th of 34 higher than 6 of 34 other Cirrhosis, Liver trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cirrhosis, Liver trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Molecular Mechanism of Exercise in Cirrhosis
RECRUITING · NA
-
HMB Enriched Amino Acids to Reverse Muscle Loss in Cirrhosis
RECRUITING · NA
-
Initial Resuscitation for Acute Kidney Injury in Cirrhosis
RECRUITING · NA
-
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
RECRUITING · NA
-
LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease
RECRUITING · NA
-
Testing LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI